Qiagen NV (QGEN) - Total Liabilities

Latest as of March 2026: $2.45 Billion USD

Based on the latest financial reports, Qiagen NV (QGEN) has total liabilities worth $2.45 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Qiagen NV - Total Liabilities Trend (1995–2025)

This chart illustrates how Qiagen NV's total liabilities have evolved over time, based on quarterly financial data. See QGEN working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Qiagen NV Competitors by Total Liabilities

The table below lists competitors of Qiagen NV ranked by their total liabilities.

Company Country Total Liabilities
SpareBank 1 Sør-Norge ASA
OL:SB1NO
Norway Nkr463.05 Billion
Canadian Utilities Limited
TO:CU
Canada CA$17.77 Billion
Inpost SA
AS:INPST
Netherlands €13.48 Billion
Jiangsu Leadmicro Nano Technology Co. Ltd. A
SHG:688147
China CN¥5.54 Billion
Red Electrica Corporacion SA
F:RE2
Germany €10.03 Billion
South Bow Corporation
TO:SOBO
Canada CA$8.59 Billion
The Gap, Inc.
NYSE:GAP
USA $8.48 Billion
Shandong Nanshan Aluminium Co Ltd
SHG:600219
China CN¥12.87 Billion

Liability Composition Analysis (1995–2025)

This chart breaks down Qiagen NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Qiagen NV stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.21 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.74 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.42 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Qiagen NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Qiagen NV (1995–2025)

The table below shows the annual total liabilities of Qiagen NV from 1995 to 2025.

Year Total Liabilities Change
2025-12-31 $2.52 Billion +18.64%
2024-12-31 $2.12 Billion -8.02%
2023-12-31 $2.31 Billion -18.21%
2022-12-31 $2.82 Billion -7.52%
2021-12-31 $3.05 Billion -0.70%
2020-12-31 $3.07 Billion +13.81%
2019-12-31 $2.70 Billion -13.31%
2018-12-31 $3.11 Billion +24.66%
2017-12-31 $2.50 Billion +46.82%
2016-12-31 $1.70 Billion +4.51%
2015-12-31 $1.63 Billion -9.39%
2014-12-31 $1.80 Billion +31.65%
2013-12-31 $1.36 Billion -2.64%
2012-12-31 $1.40 Billion +16.93%
2011-12-31 $1.20 Billion -16.62%
2010-12-31 $1.44 Billion -4.49%
2009-12-31 $1.51 Billion +5.16%
2008-12-31 $1.43 Billion +3.50%
2007-12-31 $1.38 Billion +114.14%
2006-12-31 $645.85 Million +105.13%
2005-12-31 $314.84 Million +0.20%
2004-12-31 $314.22 Million +44.71%
2003-12-31 $217.14 Million +13.40%
2002-12-31 $191.48 Million +32.98%
2001-12-31 $143.99 Million +119.22%
2000-12-31 $65.68 Million +18.44%
1999-12-31 $55.45 Million +65.04%
1998-12-31 $33.60 Million +34.94%
1997-12-31 $24.90 Million +34.59%
1996-12-31 $18.50 Million +32.14%
1995-12-31 $14.00 Million --

About Qiagen NV

NYSE:QGEN USA Diagnostics & Research
Market Cap
$7.62 Billion
Market Cap Rank
#2757 Global
#975 in USA
Share Price
$36.95
Change (1 day)
+1.01%
52-Week Range
$32.63 - $55.66
All Time High
$56.87
About

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technol… Read more